Solicitation of Nomination for Appointment to the Chronic Fatigue Syndrome Advisory Committee, 43133-43134 [E9-20568]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 164 / Wednesday, August 26, 2009 / Notices
The Department makes every effort to
ensure that the membership of HHS
Federal advisory committees is fairly
balanced in terms of points of view
represented and the committee’s
function. Every effort is made that a
broad representation of geographic
areas, gender, ethnic and minority
groups, and the disabled are given
consideration for membership on HHS
Federal advisory committees.
Appointment to the Council shall be
made without discrimination on the
basis of age, race, ethnicity, gender,
sexual orientation, disability, and
cultural, religious, or socioeconomic
status.
The Standards of Ethical Conduct for
Employees of the Executive Branch are
applicable to individuals who are
appointed as public members of Federal
advisory committees. Individuals
appointed to serve as public members of
Federal advisory committees are
classified as special Government
employees (SGEs). SGEs are
Government employees for purposes of
the conflict of interest laws. Therefore,
individuals appointed to serve as public
members of HHS are subject to an ethics
review. The ethics review is conducted
to determine if the individual has any
interests and/or activities in the private
sector that may conflict with
performance of their official duties as a
member of the Council. Individuals
appointed to serve as public members of
the Council will be required to disclose
information regarding financial
holdings, consultancies, and research
grants and/or contracts.
Dated: August 20, 2009.
Christopher H. Bates,
Director, Office of HIV/AIDS Policy, Interim
Executive Director, Presidential Advisory
Council on HIV/AIDS.
[FR Doc. E9–20571 Filed 8–25–09; 8:45 am]
BILLING CODE 4150–43–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Solicitation of Nomination for
Appointment to the Chronic Fatigue
Syndrome Advisory Committee
jlentini on DSKJ8SOYB1PROD with NOTICES
AGENCY: Department of Health and
Human Services, Office of the Secretary,
Office of Public Health and Science.
ACTION: Notice.
42 U.S.C. 217a, section 222
of the Public Health Service (PHS) Act,
as amended. The committee is governed
by the provisions of Public Law 92–463,
as amended (5 U.S.C. App 2), which sets
forth standards for the formation and
use of advisory committees.
AUTHORITY:
VerDate Nov<24>2008
17:05 Aug 25, 2009
Jkt 217001
SUMMARY: The Office of Public Health
and Science, Office on Women’s Health,
HHS, is seeking nominations of
qualified candidates to be considered
for appointment as a member of the
Chronic Fatigue Syndrome Advisory
Committee (CFSAC). CFSAC provides
science-based advice and
recommendations to the Secretary of
Health and Human Services, through
the Assistant Secretary for Health, on a
broad range of issues and topics
pertaining to chronic fatigue syndrome
(CFS). CFSAC, which was formerly
known as the Chronic Fatigue
Syndrome Coordinating Committee, was
established by the Secretary of Health
and Human Services on September 5,
2002. The appointments of five
Committee members are scheduled to
end on January 3, 2010. Nominations of
qualified candidates are being sought to
fill these scheduled vacancies.
DATES: Nominations for membership on
the Committee must be received no later
than 5 p.m. EDT on September 20, 2009,
at the address listed below.
ADDRESSES: All nominations should be
mailed or delivered to Wanda K. Jones,
DrPH, Executive Secretary, Chronic
Fatigue Syndrome Advisory Committee;
Office on Women’s Health; Department
of Health and Human Services; 200
Independence Avenue, SW.; Room
712E; Washington, DC, 20201.
FOR FURTHER INFORMATION CONTACT:
Wanda K. Jones, Dr.P.H.; Department of
Health and Human Services; 200
Independence Avenue, SW; Room 712E;
Washington, DC 20201; (202) 690–7650.
SUPPLEMENTARY INFORMATION: CFSAC
was established on September 5, 2002.
The Committee was established to
advise, consult with, and make
recommendations to the Secretary,
through the Assistant Secretary for
Health, on a broad range of topics
including (1) the current state of the
knowledge and research about the
epidemiology and risk factors relating to
chronic fatigue syndrome, and
identifying potential opportunities in
these areas; (2) current and proposed
diagnosis and treatment methods for
chronic fatigue syndrome; and (3)
development and implementation of
programs to inform the public, health
care professionals, and the biomedical,
academic, and research communities
about chronic fatigue syndrome
advances.
Nominations
The Office on Women’s Health is
requesting nominations to fill five
positions for the CFSAC. The positions
are scheduled to become vacant on
January 3, 2010. The Committee is
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
43133
composed of seven scientists with
demonstrated expertise in biomedical
research and four individuals with
demonstrated expertise in health
services, insurance, or voluntary
organizations concerned with the
problems of individuals with CFS. The
vacant positions include all four
categories. To qualify for consideration
of appointment to the Committee, an
individual must possess demonstrated
experience and expertise in the
designated fields or disciplines, as well
as expert knowledge of the broad issues
and topics pertinent to chronic fatigue
syndrome.
Individuals selected for appointment
to the Committee will serve as voting
members. Individuals selected for
appointment to the Committee can be
invited to serve terms of up to four
years. Committee members receive a
stipend for attending Committee
meetings and conducting other business
in the interest of the Committee.
Committee members also are authorized
to receive per diem and reimbursement
for travel expenses incurred for
conducting Committee business.
Nominations should be typewritten.
The following information should be
included in the package of material
submitted for each individual being
nominated for consideration: (1) A letter
of nomination that clearly states the
name and affiliation of the nominee, the
basis for the nomination (i.e., specific
attributes which qualify the nominee for
service in this capacity), and a statement
that the nominee is willing to serve as
a member of the Committee; (2) the
nominator’s name, address, and daytime
telephone number, and the home and/
or work address, telephone number, and
e-mail address of the individual being
nominated; and (3) a current copy of the
nominee’s curriculum vitae. Federal
employees should not be nominated for
consideration of appointment to this
Committee.
The Department makes every effort to
ensure that the membership of HHS
Federal advisory committees is fairly
balanced in terms of points of view
represented and the committee’s
function. Every effort is made to ensure
that a broad representation of
geographic areas, females, ethnic and
minority groups, and people with
disabilities are given consideration for
membership on HHS Federal advisory
committees. Appointment to this
Committee shall be made without
discrimination on the basis of age, race,
ethnicity, gender, sexual orientation,
disability, and cultural, religious, or
socioeconomic status. Nominations
must state that the nominee is willing to
serve as a member of CFSAC and
E:\FR\FM\26AUN1.SGM
26AUN1
43134
Federal Register / Vol. 74, No. 164 / Wednesday, August 26, 2009 / Notices
appears to have no conflict of interest
that would preclude membership.
Potential candidates are required to
provide detailed information concerning
such matters as financial holdings,
consultancies, and research grants or
contracts to permit evaluation of
possible sources of conflict of interest.
Dated: August 21, 2009.
Wanda K. Jones,
Executive Secretary, Chronic Fatigue
Syndrome Advisory Committee.
[FR Doc. E9–20568 Filed 8–25–09; 8:45 am]
BILLING CODE 4150–42–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0393]
Acrylamide in Food; Request for
Comments and for Scientific Data and
Information
AGENCY:
Food and Drug Administration,
HHS.
ACTION: Notice; request for comments
and scientific data and information.
SUMMARY: The Food and Drug
Administration (FDA) is requesting
comments and scientific data and
information on acrylamide in food.
Acrylamide is a chemical that can form
in some foods during certain types of
high-temperature cooking. FDA is
seeking information on practices that
manufacturers have used to reduce
acrylamide in food and the reductions
they have been able to achieve in
acrylamide levels. FDA is considering
issuing guidance for industry on
reduction of acrylamide levels in food
products.
DATES: Submit comments and scientific
data and information by November 24,
2009.
Submit written comments
and scientific data and information to
the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments and scientific data
and information to https://
www.regulations.gov.
jlentini on DSKJ8SOYB1PROD with NOTICES
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Lauren Posnick Robin, Center for Food
Safety and Applied Nutrition (HFS–
317), Food and Drug Administration,
5100 Paint Branch Pkwy., College Park,
MD 20740, 301–436–1639.
SUPPLEMENTARY INFORMATION:
VerDate Nov<24>2008
17:05 Aug 25, 2009
Jkt 217001
I. Background
A. Introduction
In 2002, scientists in Sweden
announced the discovery of the
chemical acrylamide in a variety of
heated foods (Ref. 1). Further research
subsequently determined that
acrylamide can form in some foods
during certain types of high-temperature
cooking (Refs. 2 and 3). Acrylamide in
food is a concern because it has been
found to be carcinogenic in rodents and
is therefore considered a potential
carcinogen for humans (Refs. 4 and 5).
Since the identification of acrylamide
in food, research around the world has
centered on measuring acrylamide
exposure in the diet, studying the
toxicology and epidemiology of
acrylamide exposure, and reducing
(mitigating) acrylamide levels in food.
Information on FDA’s activities on
acrylamide can be found on FDA’s Web
site (Ref. 6). FDA’s research program has
focused on toxicology but has also
included research on mitigation for
consumers (Ref. 7). Based on this
research and other findings, FDA added
information to its Web site in 2008 for
consumers interested in reducing their
acrylamide exposure from food.
However, FDA’s general advice for
acrylamide and eating is for consumers
to adopt a healthy eating plan consistent
with the Dietary Guidelines for
Americans (Refs. 6 and 8). The Dietary
Guidelines for Americans suggests a diet
that emphasizes fruits, vegetables,
whole grains, and fat-free or low-fat
milk and milk products; includes lean
meats, poultry, fish, beans, eggs, and
nuts; and is low in saturated fats, trans
fats, cholesterol, salt (sodium), and
added sugars.
FDA has not issued guidance for
manufacturers on reducing acrylamide
in food. However, it is anticipated that
new information will soon be available
about the toxicology of acrylamide,
which may confirm acrylamide’s
carcinogenicity in laboratory animals.
International efforts to develop
approaches to acrylamide mitigation are
also beginning to prove successful.
Moreover, FDA is aware that at least
some manufacturers in the United States
are seeking ways to reduce acrylamide
in their products. For these reasons,
FDA is considering issuing guidance for
industry on reduction of acrylamide
levels in food products.
This document summarizes
information available to FDA about
acrylamide formation, exposure,
toxicology, levels in food, and
techniques to mitigate acrylamide. This
notice also identifies areas in which
additional data and information would
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
be helpful to FDA in learning more
about acrylamide mitigation techniques
and levels of acrylamide in food. These
areas are outlined in more detail in
section II of this document.
B. Formation and Exposure
Acrylamide forms in foods primarily
from a reaction between asparagine, an
amino acid, and reducing sugars such as
glucose and fructose. This reaction is
part of the Maillard reaction, which
leads to color, flavor, and aroma
changes in cooked foods (Refs. 2, 3, and
9). Acrylamide formation usually occurs
at elevated temperatures used when
frying or baking (above 120 °C (248 °F))
and in low moisture conditions,
although acrylamide has also been
identified in some fruit and vegetable
products heated at lower temperatures
or higher moisture conditions (Refs. 10
through 13). Also, formation occurs
primarily in plant-based foods, notably
potato products such as French fries and
potato chips; coffee; and cereal-grainbased foods such as cookies, crackers,
breakfast cereals, and toasted bread.
Thousands of food samples have been
analyzed for acrylamide since 2002.
Based on its own database of acrylamide
levels in U.S. foods (Refs. 12 and 13),
FDA estimates acrylamide intake for the
average U.S. consumer as 0.4
microgram/kilogram body weight/day
(μg/kg-bw/d) (Ref. 14). International
estimates for the average consumer
range from 0.2 to 1.4 μg/kg-bw/d (Ref.
15). Based on estimates from different
countries, the Joint Food and
Agriculture Organization/World Health
Organization (FAO/WHO) Expert
Committee on Food Additives (JECFA)
identified an average acrylamide intake
of 1 μg/kg-bw/d for the general
consumer and 4 μg/kg-bw/d for high
consumers (Ref. 4).
Based on measured levels of
acrylamide in certain foods and on how
frequently these foods are consumed in
the United States, FDA identified the
following 10 foods (in ranked order) that
contribute the most acrylamide to the
U.S. diet: French fries (restaurant
prepared), French fries (oven baked),
potato chips, breakfast cereals, cookies,
brewed coffee, toast, pies and cakes,
crackers, and soft (nontoasted) breads
(Ref. 14). The JECFA evaluation
concurred that the major foods
contributing to total exposure for most
countries were French fries, potato
chips, coffee, pastry and sweet cookies,
and breads and toasts (Ref. 4).
C. Toxicology
Several international toxicology
evaluations of acrylamide have been
completed since the identification of
E:\FR\FM\26AUN1.SGM
26AUN1
]]>Agencies
[Federal Register Volume 74, Number 164 (Wednesday, August 26, 2009)]
[Notices]
[Pages 43133-43134]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-20568]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Solicitation of Nomination for Appointment to the Chronic Fatigue
Syndrome Advisory Committee
AGENCY: Department of Health and Human Services, Office of the
Secretary, Office of Public Health and Science.
ACTION: Notice.
-----------------------------------------------------------------------
AUTHORITY: 42 U.S.C. 217a, section 222 of the Public Health Service
(PHS) Act, as amended. The committee is governed by the provisions of
Public Law 92-463, as amended (5 U.S.C. App 2), which sets forth
standards for the formation and use of advisory committees.
SUMMARY: The Office of Public Health and Science, Office on Women's
Health, HHS, is seeking nominations of qualified candidates to be
considered for appointment as a member of the Chronic Fatigue Syndrome
Advisory Committee (CFSAC). CFSAC provides science-based advice and
recommendations to the Secretary of Health and Human Services, through
the Assistant Secretary for Health, on a broad range of issues and
topics pertaining to chronic fatigue syndrome (CFS). CFSAC, which was
formerly known as the Chronic Fatigue Syndrome Coordinating Committee,
was established by the Secretary of Health and Human Services on
September 5, 2002. The appointments of five Committee members are
scheduled to end on January 3, 2010. Nominations of qualified
candidates are being sought to fill these scheduled vacancies.
DATES: Nominations for membership on the Committee must be received no
later than 5 p.m. EDT on September 20, 2009, at the address listed
below.
ADDRESSES: All nominations should be mailed or delivered to Wanda K.
Jones, DrPH, Executive Secretary, Chronic Fatigue Syndrome Advisory
Committee; Office on Women's Health; Department of Health and Human
Services; 200 Independence Avenue, SW.; Room 712E; Washington, DC,
20201.
FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr.P.H.; Department of
Health and Human Services; 200 Independence Avenue, SW; Room 712E;
Washington, DC 20201; (202) 690-7650.
SUPPLEMENTARY INFORMATION: CFSAC was established on September 5, 2002.
The Committee was established to advise, consult with, and make
recommendations to the Secretary, through the Assistant Secretary for
Health, on a broad range of topics including (1) the current state of
the knowledge and research about the epidemiology and risk factors
relating to chronic fatigue syndrome, and identifying potential
opportunities in these areas; (2) current and proposed diagnosis and
treatment methods for chronic fatigue syndrome; and (3) development and
implementation of programs to inform the public, health care
professionals, and the biomedical, academic, and research communities
about chronic fatigue syndrome advances.
Nominations
The Office on Women's Health is requesting nominations to fill five
positions for the CFSAC. The positions are scheduled to become vacant
on January 3, 2010. The Committee is composed of seven scientists with
demonstrated expertise in biomedical research and four individuals with
demonstrated expertise in health services, insurance, or voluntary
organizations concerned with the problems of individuals with CFS. The
vacant positions include all four categories. To qualify for
consideration of appointment to the Committee, an individual must
possess demonstrated experience and expertise in the designated fields
or disciplines, as well as expert knowledge of the broad issues and
topics pertinent to chronic fatigue syndrome.
Individuals selected for appointment to the Committee will serve as
voting members. Individuals selected for appointment to the Committee
can be invited to serve terms of up to four years. Committee members
receive a stipend for attending Committee meetings and conducting other
business in the interest of the Committee. Committee members also are
authorized to receive per diem and reimbursement for travel expenses
incurred for conducting Committee business.
Nominations should be typewritten. The following information should
be included in the package of material submitted for each individual
being nominated for consideration: (1) A letter of nomination that
clearly states the name and affiliation of the nominee, the basis for
the nomination (i.e., specific attributes which qualify the nominee for
service in this capacity), and a statement that the nominee is willing
to serve as a member of the Committee; (2) the nominator's name,
address, and daytime telephone number, and the home and/or work
address, telephone number, and e-mail address of the individual being
nominated; and (3) a current copy of the nominee's curriculum vitae.
Federal employees should not be nominated for consideration of
appointment to this Committee.
The Department makes every effort to ensure that the membership of
HHS Federal advisory committees is fairly balanced in terms of points
of view represented and the committee's function. Every effort is made
to ensure that a broad representation of geographic areas, females,
ethnic and minority groups, and people with disabilities are given
consideration for membership on HHS Federal advisory committees.
Appointment to this Committee shall be made without discrimination on
the basis of age, race, ethnicity, gender, sexual orientation,
disability, and cultural, religious, or socioeconomic status.
Nominations must state that the nominee is willing to serve as a member
of CFSAC and
[[Page 43134]]
appears to have no conflict of interest that would preclude membership.
Potential candidates are required to provide detailed information
concerning such matters as financial holdings, consultancies, and
research grants or contracts to permit evaluation of possible sources
of conflict of interest.
Dated: August 21, 2009.
Wanda K. Jones,
Executive Secretary, Chronic Fatigue Syndrome Advisory Committee.
[FR Doc. E9-20568 Filed 8-25-09; 8:45 am]
BILLING CODE 4150-42-P
